Pfizer announces availability of data from Phase 2 breast cancer study

Pfizer announced that results from the Phase 2 PALLET study of Ibrance will be presented at the 41st Annual San Antonio Breast Cancer Symposium, or SABCS. The abstract is now accessible on the SABCS website ahead of the oral presentation on December 6, Pfizer noted. The abstract for the study states that 307 patients were recruited and that 103 were randomized to letrozole alone and 204 to letrozole + palbociclib. “Clinical response was not significantly different between letrozole vs letrozole + palbociclib groups, nor was the small proportion of patients with pathological CR,” the abstract states. The conclusion of the abstract reads: “Adding palbociclib to letrozole markedly enhanced the suppression of malignant cell proliferation as assessed by Ki67 but did not substantially increase the clinical response of primary ER+ breast cancer over a 14-week period. Concurrent reductions in cell death may have reduced the speed of tumor shrinkage.”
https://thefly.com/landingPageNews.php?id=2821769